undamentalytics Newsletter
Sign in

Praxis Precision Medicines, Inc. (PRAX) stock

Add to watchlist

Add holding +

NASDAQ: PRAX Nasdaq Biotechnology Next results ~November 9, 2026

Praxis Precision Medicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 22% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Praxis Precision Medicines, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 73% and a beta of 1.3 against the S&P 500.
  • Insiders selling. 3 insiders sold $11M of stock over the past 365 days and none bought (33% under pre-set trading plans).
  • Heavily shorted. 14.1% of the shares available to trade are sold short (7.1 days of average volume to cover).

Latest results

Earnings per share
-$2.87 against an average estimate of -$3.69: beat by 22.2%
Share reaction
+13.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$3.63

Praxis Precision Medicines' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week+2.5%
  • 1 month-7.3%
  • This year-7.0%
  • 1 year+37.8%
  • 5 years-16.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Praxis Precision Medicines, Inc. valuation models and calculator

No model value for Praxis Precision Medicines, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $0 and EPS of −$3.63 (range −$5.60 to −$2.74) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$14.02 −4% $830710 0%
Next −$9.50 +32% $345m +41443%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −8.5% on 90 days ago. In the last 30 days, 15 analysts raised Praxis Precision Medicines, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Praxis Precision Medicines, Inc., last 90 days
−$20.00 −$15.00 −$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$15.32 Current fiscal year, 60 days ago: −$13.94 Current fiscal year, 30 days ago: −$13.94 Current fiscal year, 7 days ago: −$13.91 Current fiscal year, Now: −$14.02 −$14.02 Next fiscal year, 90 days ago: −$9.66 Next fiscal year, 60 days ago: −$9.29 Next fiscal year, 30 days ago: −$9.29 Next fiscal year, 7 days ago: −$9.14 Next fiscal year, Now: −$9.50 −$9.50

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$15.32−$9.66
60 days ago −$13.94−$9.29
30 days ago −$13.94−$9.29
7 days ago −$13.91−$9.14
Now −$14.02−$9.50

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$3.69 −$2.87 +22.2%
Mar 2026 −$3.68 −$3.20 +13.0%
Dec 2025 −$3.13 −$3.50 −12.0%
Sept 2025 −$3.49 −$3.36 +3.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

21 analysts, Oct 2026
Buy1990%
Hold15%
Sell15%

Monthly trend

  1. Oct 202641521
  2. Sep 202631419
  3. Aug 202631419
  4. Jul 202631419

Counts of recommendations published by analysts covering Praxis Precision Medicines, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.1%
of tradable shares
Days to cover
7.11
at average volume
Short interest, 1 month
+3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.3%
of shares
Employees
168
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PRAX−64%−88%−38%+245%+283%−7%
Industry peers (median)−35%−56%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PRAX25%33%58%58%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PRAX−78%−92%−84%−41%−69%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 16, 2020: 99% from January 7, 2021 to March 30, 2023. Getting back needed a 7388% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$164.09 – $386.33
From 52-week high
−29.1%
vs 50-day average
−8.4%
vs 200-day average
−12.9%
Volatility (1 year)
73%
Beta vs S&P 500
1.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±8.1%
After a week
9 up, 3 down
typical move ±10.4%
After a month
5 up, 7 down
typical move ±20.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +13.0% +0.5% +15.4% +10.2%
May 7, 2026 −2.4% +0.5% +2.2% −25.1%
February 19, 2026 +1.9% +0.5% +3.5% −9.3%
January 6, 2026 +5.7% +0.3% +1.4% +10.4%
November 5, 2025 +0.3% −0.7% +6.9% +44.4%
August 4, 2025 −11.6% +1.0% −16.9% −13.9%
May 2, 2025 +2.4% +0.9% +0.8% +8.3%
February 28, 2025 −48.4% −0.2% −40.8% −41.8%
January 29, 2025 +1.1% +0.1% +17.1% −48.8%
November 6, 2024 +3.6% +3.3% +12.4% −4.0%
August 13, 2024 −1.1% +2.0% +0.1% +13.3%
May 13, 2024 −5.9% +0.5% −7.7% −15.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$11.3B
Institutions reporting
308
Shares held vs prior quarter
▲ 5.9%
Positions opened / closed
56 / 38

Top buyers and sellers, Q2 2026: 177 institutions bought and 131 sold ; the biggest buyer was Vanguard Portfolio Management LLC (+578K shares) and the biggest seller Orbis Allan Gray Ltd (−943K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jupiter Topco LLC $1.1B 3.4M 10.2% —
FMR LLC $776M 2.3M 6.9% ▲ 7.2%
Blackrock, Inc. $768M 2.3M 6.8% ▼ 1.4%
Perceptive Advisors LLC $682M 2.0M 6.0% 0.0%
Baker Bros. Advisors LP $587M 1.8M 5.2% 0.0%
Orbis Allan Gray Ltd $512M 1.5M 4.5% ▼ 38.1%
Vanguard Portfolio Management LLC $447M 1.3M 4.0% ▲ 76.4%
Vanguard Capital Management LLC $414M 1.2M 3.7% ▲ 1.1%
State Street Corp $344M 1.0M 3.0% ▲ 16.1%
Adage Capital Partners Gp, L.L.C. $340M 1.0M 3.0% ▲ 24.5%
Deerfield Management Company, L.P. $323M 963K 2.9% 0.0%
Driehaus Capital Management LLC $321M 959K 2.8% ▲ 1.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Praxis Precision Medicines, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $11.1M 18 trades by 3 insiders · 33% under pre-set plans
Net ▼ $11.1M net selling
Insider Date Trade Shares Price Value
Desimone Jill Director June 24, 2026 Sell pre-set plan 120 $303.13 $36,376
Desimone Jill Director June 24, 2026 Sell pre-set plan 320 $305.31 $97,699
Desimone Jill Director June 24, 2026 Sell pre-set plan 683 $306.77 $209,524
Desimone Jill Director June 24, 2026 Sell pre-set plan 1,240 $308.24 $382,218
Desimone Jill Director June 24, 2026 Sell pre-set plan 999 $309.38 $309,071
Desimone Jill Director June 24, 2026 Sell pre-set plan 1,750 $310.89 $544,058
Desimone Jill Director June 24, 2026 Sell pre-set plan 2,854 $311.91 $890,191
Desimone Jill Director June 24, 2026 Sell pre-set plan 1,004 $312.83 $314,081
Desimone Jill Director June 24, 2026 Sell pre-set plan 504 $313.66 $158,085
Desimone Jill Director June 24, 2026 Sell pre-set plan 837 $315.71 $264,249
Desimone Jill Director June 24, 2026 Sell pre-set plan 1,279 $314.90 $402,757
Desimone Jill Director June 24, 2026 Sell pre-set plan 10 $301.44 $3,014

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 0 sales of Praxis Precision Medicines, Inc. shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded September 29, 2026, filed October 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded July 30, 2026, filed September 4, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 15, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 19, 2026
  • January 6, 2026
  • November 5, 2025
  • August 4, 2025

Recent SEC filings

Data status

When each part of this page on Praxis Precision Medicines, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Praxis Precision Medicines, Inc. in brief

What does Praxis Precision Medicines, Inc. do?
Praxis Precision Medicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Praxis Precision Medicines, Inc.'s stock ticker?
Praxis Precision Medicines, Inc. trades under the ticker PRAX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Praxis Precision Medicines, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jupiter Topco LLC, FMR LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Praxis Precision Medicines, Inc. stock?
Over the last 12 months, Praxis Precision Medicines, Inc.'s directors and officers reported 0 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Praxis Precision Medicines, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Praxis Precision Medicines, Inc. announces its own schedule.